Viking Therapeutics VKTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -70%-22.7pp | -47.3%-18.1pp | -29.2%-9.2pp | -20%-5.6pp | -14.4%+3.5pp | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 5.7×-3.6× | 9.3×-19.0× | 28.3×+2.5× | 25.9×-18.4× | 44.2×+11.2× | |
| Per Share | ||||||
| Book value per share | $4.34-23.4% | $5.67-10.7% | $6.35-10.5% | $7.09-6.1% | $7.56-6.4% | |
| Valuation | ||||||
| Market capitalization | $3.76B-5.4% | $3.98B+34.6% | $2.96B-2.4% | $3.03B+11.7% | $2.71B-39.5% | |
| Price / book | 7.5×+1.3× | 6.2×+2.1× | 4.1×+0.3× | 3.8×+0.6× | 3.2×-1.9× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Viking Therapeutics's ratios come from?
- Every ratio is computed from Viking Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.